Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Adjusted net profit stood at Rs 2,792.38 crore, down 10.44% year on year from Rs 3,117.95 crore. Sequentially, adjusted net profit declined 8.14% from Rs 3,039.73 crore.
EBITDA increased 4.8% year on year to Rs 4,743.9 crore, while EBITDA margin stood at 29.3%. Research and development investment was Rs 778.4 crore, equivalent to 4.8% of sales.
Profit before tax stood at Rs 3,159.37 crore in Q2 FY27, down 22.92% vs previous quarter and 24.19% vs year-ago quarter.
Total expenditure increased 14.35% year on year to Rs 12,213.16 crore from Rs 10,680.76 crore. Raw material consumption rose 43% to Rs 2,318.70 crore, while employee expenses increased 18.42% to Rs 3,274.16 crore. Interest costs declined 25.23% to Rs 74.67 crore, while depreciation and amortisation increased 3.95% to Rs 758.34 crore.
India formulation sales increased 17.3% year on year to Rs 5,552.3 crore, accounting for 34.5% of consolidated sales. US formulation sales declined 8.2% to US$455 million. Emerging Markets formulation sales grew 7.6% to US$350 million, while Rest of World sales increased 3.1% to US$241 million.
Global Innovative Medicines sales rose 6.9% year on year to US$356 million, contributing 21.1% of consolidated sales. API external sales increased 13.7% YoY to Rs 488.9 crore in Q2 FY27.
Managing director Kirti Ganorkar said quarterly performance was supported by strong momentum in India, Emerging Markets and Rest of World. He highlighted the US approval of Ilumya for adults with active psoriatic arthritis and the licensing of lerodalcibep, a PCSK9 inhibitor, for markets outside the US and China.
The company said integration planning for the Organon acquisition was progressing as scheduled, with regulatory approvals secured in most regions and the remaining approvals tracking as planned.
On 27 April 2026, the group entered into a definitive agreement to acquire all outstanding shares of Organon & Co. for US$14 per share in an all-cash transaction, valuing the enterprise at US$11.75 billion. The acquisition remains subject to regulatory approvals and other closing conditions.
Sun Pharmaceutical Industries is a global pharmaceutical company with businesses across innovative medicines, generics and consumer healthcare. It is India's largest pharmaceutical company and has a presence in the US and emerging markets. Its innovative medicines portfolio focuses on dermatology, ophthalmology and onco-dermatology, contributing about 22% of sales. The company operates manufacturing facilities across five continents and supplies medicines to customers in over 100 countries.
Shares of Sun Pharmaceutical Industries rose 0.95% to settle at Rs 1,777.70 on 30 October 2026.
Sun Pharmaceutical Industries announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA).
'FDA approval of ILUMYA for adults with active psoriatic arthritis represents another important innovative medicine milestone for Sun Pharma and builds on the established clinical experience of ILUMYA in plaque psoriasis,” said Rick Ascroft, North America CEO, Sun Pharma. 'As an IL-23 inhibitor administered exclusively by a healthcare provider, ILUMYA is now an option for adults with active psoriatic arthritis who are unable to self-administer treatment or who may benefit from regular in-office care.'
The base issue size of Rs 7,000 crore was fully subscribed and, based on the bids received and accepted, the Company exercised the greenshoe option to the extent of Rs 816 crore, out of the greenshoe option of up to Rs 3,000 crore.
Sun Pharmaceutical Industries announced that UNLOXCYT® (cosibelimab-ipdl) has been elevated to a National Comprehensive Cancer Network® (NCCN®) Category 2A recommended option for patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) who are not candidates for curative surgery or curative radiation.
This is an addition to the Category 2A designation in metastatic cutaneous squamous cell carcinoma (mCSCC), which was assigned to UNLOXCYT in 2025.
UNLOXCYT was approved by the U.S. Food and Drug Administration (FDA) in 2024 and is indicated for the treatment of adults with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation. The recommended dosage of UNLOXCYT is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks. UNLOXCYT is the first and only FDA approved PD-L1-blocking antibody for advanced CSCC (aCSCC).
The evidence submitted to NCCN in support of the change was based on the pivotal registration study, in which 55% of patients achieved an objective response, including 26% who achieved a complete response. Responses were durable: at a median follow-up of 24.1 months; median duration of response had not been reached (range: 8.3 to 31.3+ months). In addition, fewer than 1% of patients experienced a high-grade (Grade 3-5) immune-mediated adverse reaction (imARs)—an important consideration in this patient population. There were no grade 4 or 5 imARs.
NCCN is an alliance of 34 leading cancer centers in the U.S. Its Clinical Practice Guidelines in Oncology, referred to as the NCCN Guidelines, provide recommendations for the prevention, diagnosis, evaluation, and treatment of different types of cancer. The NCCN Guidelines are among the most influential clinical guidelines in cancer care, offering evidence-based, expert developed recommendations intended to help clinicians make treatment decisions for patients with cancer.
CreditAccess Grameen Ltd, Sun Pharmaceutical Industries Ltd, Bharti Hexacom Ltd, Page Industries Ltd are among the other stocks to see a surge in volumes on BSE today, 21 October 2026.
L&T Technology Services Ltd recorded volume of 3.07 lakh shares by 10:45 IST on BSE, a 38.53 times surge over two-week average daily volume of 7976 shares. The stock gained 10.85% to Rs.4,001.55. Volumes stood at 6411 shares in the last session.
CreditAccess Grameen Ltd recorded volume of 2.11 lakh shares by 10:45 IST on BSE, a 19.13 times surge over two-week average daily volume of 11010 shares. The stock lost 3.37% to Rs.1,185.25. Volumes stood at 4791 shares in the last session.
Sun Pharmaceutical Industries Ltd clocked volume of 2.82 lakh shares by 10:45 IST on BSE, a 3.8 times surge over two-week average daily volume of 74100 shares. The stock lost 0.40% to Rs.1,738.05. Volumes stood at 39660 shares in the last session.
Bharti Hexacom Ltd witnessed volume of 1.63 lakh shares by 10:45 IST on BSE, a 3.73 times surge over two-week average daily volume of 43589 shares. The stock increased 2.17% to Rs.1,667.70. Volumes stood at 1.1 lakh shares in the last session.
Page Industries Ltd registered volume of 5526 shares by 10:45 IST on BSE, a 3.35 fold spurt over two-week average daily volume of 1651 shares. The stock slipped 1.01% to Rs.35,343.00. Volumes stood at 10223 shares in the last session.